使用机器学习识别关键基因特征,用于预测化学免疫治疗在扩展阶段小细胞肺癌中的疗效
Daichi Fujimoto1, Ryota Shibaki2, Keiichi Kimura3
1Internal Medicine III, Wakayama Medical University, Wakayama, Japan; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Lung cancer (Amsterdam, Netherlands)
|January 9, 2025
概括
研究人员使用机器学习识别了83个关键基因,以预测化学免疫疗法在扩展阶段小细胞肺癌 (ES-SCLC) 的有效性. 这种基因组可以准确预测治疗反应,帮助ES-SCLC患者开发生物标志物.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物统计学 生物统计学
背景情况:
- 在扩散阶段小细胞肺癌 (ES-SCLC) 中,化疗免疫疗法的疗效缺乏明确的预测生物标志物.
- 识别这些生物标志物对于优化患者治疗策略至关重要.
研究的目的:
- 通过机器学习 (ML) 来识别与ES-SCLC化学免疫疗法疗效相关的关键基因.
- 开发和验证一种基于基因表达的模型,用于预测治疗反应.
主要方法:
- 93名ES-SCLC患者接受一线化疗免疫治疗的前性多中心队列.
- 用于综合基因表达分析的RNA测序.
- 针对特征选择的ML技术,导致了一个83基因小组和一个用nCounter系统验证的预测模型.
主要成果:
- ML发现了83个基因的特征,可以预测治疗的疗效.
- 经验证的模型显示了高准确度 (0.93),精度 (1.00),真正阳性率 (0.83),和真负率 (1.00) 预测180天无进展生存期 (PFS).
- 被归类为高疗效的患者显示PFS显著更长 (P < 0.001).
结论:
- 这项研究为开发ES-SCLC中的新生物标志物提供了基础.
- 识别的基因组和ML模型提供了一个潜在的成本效益,快速的工具,用于评估化学免疫治疗在临床环境中的疗效.
相关概念视频
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


